CN101495627A - 用于基因疗法的延长的腺相关病毒载体的顺行性心外膜冠状动脉输注 - Google Patents

用于基因疗法的延长的腺相关病毒载体的顺行性心外膜冠状动脉输注 Download PDF

Info

Publication number
CN101495627A
CN101495627A CNA2007800283615A CN200780028361A CN101495627A CN 101495627 A CN101495627 A CN 101495627A CN A2007800283615 A CNA2007800283615 A CN A2007800283615A CN 200780028361 A CN200780028361 A CN 200780028361A CN 101495627 A CN101495627 A CN 101495627A
Authority
CN
China
Prior art keywords
infusion
polynucleotide
purposes according
serca2a
aav2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800283615A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂娜·玛丽亚·热伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Celladon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celladon Corp filed Critical Celladon Corp
Publication of CN101495627A publication Critical patent/CN101495627A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2007800283615A 2006-07-25 2007-07-16 用于基因疗法的延长的腺相关病毒载体的顺行性心外膜冠状动脉输注 Pending CN101495627A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83332406P 2006-07-25 2006-07-25
US60/833,324 2006-07-25

Publications (1)

Publication Number Publication Date
CN101495627A true CN101495627A (zh) 2009-07-29

Family

ID=38581949

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800283615A Pending CN101495627A (zh) 2006-07-25 2007-07-16 用于基因疗法的延长的腺相关病毒载体的顺行性心外膜冠状动脉输注

Country Status (13)

Country Link
US (2) US20080076730A1 (cg-RX-API-DMAC7.html)
EP (2) EP2044199B1 (cg-RX-API-DMAC7.html)
JP (2) JP5623740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090035711A (cg-RX-API-DMAC7.html)
CN (1) CN101495627A (cg-RX-API-DMAC7.html)
AU (1) AU2007277392A1 (cg-RX-API-DMAC7.html)
CA (1) CA2658628A1 (cg-RX-API-DMAC7.html)
DK (1) DK2044199T3 (cg-RX-API-DMAC7.html)
ES (1) ES2398593T3 (cg-RX-API-DMAC7.html)
GB (1) GB2437893A (cg-RX-API-DMAC7.html)
IL (1) IL196541A (cg-RX-API-DMAC7.html)
PL (1) PL2044199T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008013692A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
PH12012501579A1 (en) * 2010-01-05 2012-10-22 Michael Aaron Vertical axis variable geometry wind energy collection system
US11583662B2 (en) 2016-04-18 2023-02-21 Sardocor Corp. Methods and compositions for consistent intracoronary administration of a biologic
KR20240093919A (ko) * 2017-04-14 2024-06-24 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
CN117241855A (zh) * 2021-02-22 2023-12-15 迪纳柯公司 肝脏的局部区域灌注

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) * 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US5773289A (en) * 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
EP1053025A2 (en) * 1998-02-11 2000-11-22 The Regents of the University of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1324780A4 (en) * 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
CA2422078C (en) * 2000-09-11 2011-08-09 The Regents Of The University Of California High efficiency cardiac gene transfer
CN103589692B (zh) * 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
WO2005014835A1 (en) * 2003-07-17 2005-02-17 Bayerische Julius-Maximilians- Universität Würzburg Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis
US7291604B2 (en) * 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
EP1691609A4 (en) * 2003-12-11 2006-11-29 Mirus Bio Corp RELEASE OF VIRUS VECTORS ANEXTRAVASAL PARENCHYM CELLS
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CA2579519A1 (en) * 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
WO2006089340A2 (en) * 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2244740A1 (en) * 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium

Also Published As

Publication number Publication date
WO2008013692A2 (en) 2008-01-31
JP5623740B2 (ja) 2014-11-12
CA2658628A1 (en) 2008-01-31
US20170252462A1 (en) 2017-09-07
EP2460879A1 (en) 2012-06-06
GB0716413D0 (en) 2007-10-03
EP2044199A2 (en) 2009-04-08
WO2008013692A3 (en) 2008-05-02
IL196541A0 (en) 2009-11-18
JP2009544698A (ja) 2009-12-17
GB2437893A (en) 2007-11-07
AU2007277392A1 (en) 2008-01-31
US20080076730A1 (en) 2008-03-27
ES2398593T3 (es) 2013-03-20
IL196541A (en) 2012-12-31
EP2044199B1 (en) 2012-11-14
KR20090035711A (ko) 2009-04-10
DK2044199T3 (da) 2013-02-11
JP2014218509A (ja) 2014-11-20
PL2044199T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
CN116887868A (zh) 达农病的治疗
US20060148742A1 (en) Polynucleotide delivery to cardiac tissue
US20170312373A1 (en) Method for enhanced uptake of viral vectors in the myocardium
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EA005157B1 (ru) Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
US20250143624A1 (en) Ventricular Arrhythmias and Related Methods
EP3472196B1 (en) Neuropeptide-expressing vectors and methods for the treatment of epilepsy
TWI873173B (zh) 藥物灌注到非停止(unarrested)跳動之心臟
KR20230155424A (ko) 근이영양증을 치료하기 위한 방법 및 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090729